Pyronaridine

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Name
Pyronaridine
Accession Number
DB12975
Description

Pyronaridine has been investigated for the treatment of Malaria.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 518.06
Monoisotopic: 517.224453
Chemical Formula
C29H32ClN5O2
Synonyms
  • Pyronaridine

Pharmacology

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Indication
Not Available
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics
Not Available
Mechanism of action
Not Available
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism
Not Available
Route of elimination
Not Available
Half-life
Not Available
Clearance
Not Available
Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity
Not Available
Affected organisms
Not Available
Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcetophenazineThe risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Acetophenazine.
AlimemazineThe risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Alimemazine.
ArtemetherThe risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Artemether.
ButaperazineThe risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Butaperazine.
ChlorpromazineThe risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Chlorpromazine.
DapsoneThe risk or severity of adverse effects can be increased when Pyronaridine is combined with Dapsone.
FluphenazineThe risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Fluphenazine.
LumefantrineThe risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Lumefantrine.
MefloquineMefloquine may increase the QTc-prolonging activities of Pyronaridine.
MesoridazineThe risk or severity of QTc prolongation can be increased when Pyronaridine is combined with Mesoridazine.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Pyronaridine tetraphosphate2T289F9ACONot AvailableYKUQEKXHQFYULM-UHFFFAOYSA-N

Categories

ATC Codes
P01BF06 — Artesunate and pyronaridine
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as 4-aminoquinolines. These are organic compounds containing an amino group attached to the 4-position of a quinoline ring system.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Quinolines and derivatives
Sub Class
Aminoquinolines and derivatives
Direct Parent
4-aminoquinolines
Alternative Parents
Chloroquinolines / Naphthyridines / p-Aminophenols / Aniline and substituted anilines / Phenylmethylamines / Benzylamines / Alkyl aryl ethers / Aminopyridines and derivatives / Aralkylamines / Primary aromatic amines
show 8 more
Substituents
4-aminoquinoline / Alkyl aryl ether / Amine / Aminophenol / Aminopyridine / Aniline or substituted anilines / Aralkylamine / Aromatic heteropolycyclic compound / Aryl chloride / Aryl halide
show 26 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
Not Available

Chemical Identifiers

UNII
TD3P7Q3SG6
CAS number
74847-35-1
InChI Key
DJUFPMUQJKWIJB-UHFFFAOYSA-N
InChI
InChI=1S/C29H32ClN5O2/c1-37-26-9-8-24-28(33-26)27(23-7-6-21(30)16-25(23)32-24)31-22-14-19(17-34-10-2-3-11-34)29(36)20(15-22)18-35-12-4-5-13-35/h6-9,14-16,36H,2-5,10-13,17-18H2,1H3,(H,31,32)
IUPAC Name
4-({7-chloro-2-methoxybenzo[b]1,5-naphthyridin-10-yl}amino)-2,6-bis[(pyrrolidin-1-yl)methyl]phenol
SMILES
COC1=NC2=C(NC3=CC(CN4CCCC4)=C(O)C(CN4CCCC4)=C3)C3=CC=C(Cl)C=C3N=C2C=C1

References

General References
Not Available
PubChem Compound
5485198
PubChem Substance
347829115
ChemSpider
10647812
BindingDB
53353
ChEBI
135951
ChEMBL
CHEMBL35228
ZINC
ZINC000003882897
Wikipedia
Pyronaridine

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentMalaria caused by Plasmodium falciparum1
4Not Yet RecruitingTreatmentBurkina Faso / Plasmodium Infections1
4RecruitingTreatmentPlasmodium Falciparum Malaria (Drug Resistant)1
3CompletedTreatmentPlasmodium Infections5
3RecruitingTreatmentCoronavirus Disease 2019 (COVID‑19) / Plasmodium Infections1
3TerminatedTreatmentPlasmodium Infections1
2Active Not RecruitingTreatmentMalaria caused by Plasmodium falciparum1
2CompletedTreatmentMalaria caused by Plasmodium falciparum1
2CompletedTreatmentPlasmodium Falciparum Malaria1
2CompletedTreatmentSchistosomiasis haematobia1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
Tablet, film coated
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.0132 mg/mLALOGPS
logP5.78ALOGPS
logP4.22ChemAxon
logS-4.6ALOGPS
pKa (Strongest Acidic)7.96ChemAxon
pKa (Strongest Basic)10.08ChemAxon
Physiological Charge2ChemAxon
Hydrogen Acceptor Count7ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area73.75 Å2ChemAxon
Rotatable Bond Count7ChemAxon
Refractivity147.74 m3·mol-1ChemAxon
Polarizability57.85 Å3ChemAxon
Number of Rings6ChemAxon
Bioavailability1ChemAxon
Rule of FiveNoChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleYesChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Drug created on October 21, 2016 01:44 / Updated on February 21, 2021 18:54